Leipzig

• A Study of LY3457263 Compared to Placebo in Participants with Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide Recruiting
  2024-520328-27-00 4 2025-08-07 Type 2 Diabetes
• A study to test how BI 3031185 is tolerated by people with borderline personality disorder or attention-deficit/hyperactivity disorder. Recruiting
  2024-514296-17-00 3 2025-08-05 Attention deficit hyperactivity disorder
• Safety and Efficacy of Intravenous Thrombolysis in Patients with Ischemic Stroke on Treatment with Direct Oral Anticoagulants: DO-IT – The D … Recruiting
  2024-515561-34-01 6 2025-08-04 Acute ischemic stroke with recent ingestion of direct oral anticoagula
• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph … Recruiting
  2023-509630-19-00 5 2025-07-31 Esophageal Squamous Cell Carcinoma (ESCC)
• A trial comparing the treatment of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan to the standard treatment in patients with … Recruiting
  2024-512583-57-00 5 2025-07-30 HER2-positive locally advanced or metastatic gastric or gastroesophage
• Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION) Recruiting
  2024-519521-37-01 10 2025-07-30 Acute ischemic stroke
• A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima … Recruiting
  2024-518893-15-00 5 2025-07-29 Chronic lymphotic leukemia and Small Lymphocytic lymphoma
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Recruiting
  2024-520154-38-00 5 2025-07-29 Acute Myeloid Luekemia
• A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Parti … Recruiting
  2024-517991-39-00 5 2025-07-22 Asthma
• Recombinant coagulation Factor VIIa administered at the earliest time for the treatment of stroke caused by bleeding in the brain - FASTEST … Recruiting
  2024-517383-28-00 5 2025-07-21 Acute haemorrhagic stroke
• Evaluation of efficacy and safety of Cemiplimab as first line treatment for advanced basal cell carcinoma (CEMI-first) - An open label, sing … Recruiting
  2024-517647-31-00 4 2025-07-09 basal cell carcinoma
• A Study to Evaluate Tobevibart+Elebsiran in Participants with Chronic HDV Infection Not Virologically Suppressed with Bulevirtide Recruiting
  2024-519282-22-00 5 2025-07-09 Chronic Hepatitis D Virus (HDV) Infection
• A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting
  2024-516834-36-00 5 2025-07-08 Locally recurrent unresectable or metastatic TNBC with tumors expressi
• A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit … Recruiting
  2024-517247-31-00 5 2025-07-07 Newly Diagnosed Higher Risk Myelodysplastic Syndrome
• Master protocol of TCR-modified T cell therapy targeting HLA-restricted KRAS antigen administered in adult patients with metastatic or local … Recruiting
  2024-513900-32-00 7 2025-07-03 Pancreatic Ductal Adenocarcinoma
• A study to understand if sotagliflozin improves symptoms and is safe in people with hypertrophic cardiomyopathy Recruiting
  2024-513869-39-00 5 2025-06-27 Obstructive Cardiomyopathy, Hypertrophic
• A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting
  2024-513111-27-00 5 2025-06-26 Psoriatic Arthritis
• Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation (alloSCT) In Patients with Acute Myeloid Leu … Recruiting
  2023-509055-14-00 4 2025-06-17 myelodysplastic neoplasia (MDS)
• A Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior … Recruiting
  2024-513112-99-00 5 2025-06-13 Active Psoriatic Arthritis Stratified by Prior Biologic Use
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting
  2024-513122-27-00 5 2025-06-10 Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
• REscue of Nephrons with ALe.F02 (RENAL F02) Recruiting
  2022-502184-38-00 4 2025-06-06 Rapidly progressive glomerulonephritis
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal … Recruiting
  2024-512302-25-00 5 2025-06-06 Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
• Assessment of the safety and efficacy of a hepatitis B vaccine in adult patients with hepatitis B Recruiting
  2023-507623-36-00 9 2025-05-26 Chronic hepatitis B

Showing 193–216 of 720 trials